HOME > TOP STORIES
TOP STORIES
-
BUSINESS Amgen Japan to Cut 30 Jobs in Evenity Sales Unit as It Rejigs Organization
June 27, 2023
-
BUSINESS Japan Approves Novartis’ Gene Therapy Luxturna for Rare Eye Disease
June 27, 2023
-
ORGANIZATION FPMAJ Chief Shows Enthusiasm toward Drug Pricing Reform, Vows to Exchange Views with All Affiliate Groups
June 26, 2023
-
ORGANIZATION New JPMA Director General Keen to Make “Special Price Maintenance” Happen after 15 Years
June 23, 2023
-
REGULATORY Chuikyo Kicks Off Debates toward FY2024 Drug Price Reform
June 22, 2023
-
COMMENTARY Honebuto Policy Is Tailwind for Pharma, but Situation Remains Unpredictable
June 22, 2023
-
REGULATORY MHLW to Set Up Separate Forums Focused on Generics and Drug Lags to Execute Expert Panel Proposals
June 21, 2023
-
BUSINESS Wegovy Rollout Being Delayed due to Unprecedented Demand: Novo Japan Chief
June 21, 2023
-
REGULATORY MHLW Study Group to Develop Company Indicators for Generic Supply Systems in FY2023
June 20, 2023
-
REGULATORY MHLW Study Group Proposes Flexibility in Launch Premium Criteria, Broader Comparators
June 20, 2023
-
REGULATORY Japan OKs Honebuto Budget Policy Blueprint, Vows Debates on Longer-Term Drug Costs
June 19, 2023
-
BUSINESS As Wholesalers Try to Negotiate Higher Prices, Hospitals Face Tougher Haggling This Year
June 16, 2023
-
ORGANIZATION Lag and Loss Blamed on Drug Pricing System, JPMA Set to Get Involved in Corrective Steps: President
June 15, 2023
-
BUSINESS AstraZeneca Launches Sales Unit Dedicated to GI Cancer as Imfinzi Expands Label
June 14, 2023
-
REGULATORY LDP Policy Research Council Generally Approves Revised Honebuto Draft
June 14, 2023
-
REGULATORY MHLW Publishes Final Report by Expert Panel on Comprehensive Pharma Policy
June 13, 2023
-
ORGANIZATION Tide Has Changed, but That Doesn’t Erase Concerns: FPMAJ Drug Pricing Chief
June 12, 2023
-
BUSINESS FDA Advisors Back Full Approval of Eisai’s Alzheimer’s Med
June 12, 2023
-
BUSINESS AstraZeneca Crowned in Foreign Pharma Ranking for 2nd Year Straight, Followed by MSD
June 9, 2023
-
REGULATORY Honebuto Social Security Debate Culminates with LDP Push for Nixing Budget Cap
June 9, 2023
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
